Zheng T, et al. - This meta-analysis was carried out to evaluate the possible value of Beclin-1 in non-small-cell lung cancer (NSCLC). For this analysis, researchers searched PubMed and Embase databases for eligible studies published before December 31, 2017. Eight studies including 1,159 subjects were incorporated in this meta-analysis. The pooled results showed that high Beclin-1 expression was significantly associated with earlier tumor grade, less nodal involvement, earlier TNM stage, smaller tumor size, better differentiation, less recurrence, and better OS in NSCLC. In NSCLC, high Beclin-1 expression forecasts a better clinicopathological status and a better prognosis. Results of this study suggested that Beclin-1 might act as a promising prognostic biomarker for NSCLC.